Navigation auf uzh.ch
Navigation auf uzh.ch
More than 800 participants informed themselves at the Zurich Life Science Day on careers in academia and the privat sector.
The «4th Zurich Life Science Day 2013» took place on the 12 February, 2013 at the Irchel Campus of the University of Zurich, and offered:
At the event we counted more than 800 participants.
Time | Session A | Session B | CV-Checks |
|---|---|---|---|
8:30-9:00 | Registration | Adecco UZH Career Services ETH Career Center Kelly Scientific | |
9:00-10:00 | Welcoming & Introduction by LSZYSN Keynote Lecture by Prof. Timothy Hunt, Nobel Laureate for Physiology or Medicine 2001, Cancer Research UK | ||
10:00-10:30 | Coffee Break & Company Exhibition | ||
10:300-11:15 | Prof. Dario Neri, ETH Zurich | Careers in Developing Diagnostics Roche Diagnostics | |
11:15-12:00 | DOs and DON'Ts in the job interview ETH Career Center | Tips and Tricks on Assessment Interviews XCG Executive Consulting Group AG | |
| 12:00-13:30 | Cold Lunch & Company Exhibition | ||
| 13:30-14:15 | Opportunities in Clinical Trials University Hospital Zurich | Finding a Career in the Biopharmaceutical Industry Celgene | |
| 14:15-15:00 | Kantonsschule Wettingen | Careers in Intellectual Property Swiss Federal Institute of Intellectual Property | |
| 15:00-15:30 | Coffee Break & Company Exhibition | ||
| 15:30-16:15 | Positions as Data Analyst in Financial Services BB Biotech | GlycoVaxyn | |
| 16:15-17:15 | Consulting Careers McKinsey&Co | Scitec Media | |
| 17:15-... | Networking Apéro | ||
«Science, as I understand it, is about making discoveries that help us to comprehend Nature. I want to try to explain how I became a biochemist and talk about some of the discoveries I made and how I came to make them.»
Tim Hunt was, until his retirement in 2010, a ‘principal scientist’ (note, not THE principal scientist) at Cancer Research UK, Clare Hall Laboratories, in South Mimms, Hertfordshire. Dr Hunt was born in 1943 and grew up in Oxford, moving to Cambridge to read Natural Sciences in 1961. He obtained his Ph.D. from the Department of Biochemistry in Cambridge in 1968. He spent almost 30 years in Cambridge, working in the Department of Biochemistry on the control of protein synthesis and the cell cycle, but with spells in the USA; he was a postdoctoral Fellow at the Albert Einstein College of Medicine in 1968-70 and spent summers at the Marine Biological Laboratory, Woods Hole from 1977 until 1985, teaching laboratory courses and doing research. In 1982, he discovered cyclins, which turned out to be components of “Key Regulator(s) of the Cell Cycle” This led to a share of the Nobel Prize in Physiology or Medicine in 2001, together with Lee Hartwell and Paul Nurse. Tim Hunt was chairman of the council of EMBO (European Molecular Biology Organisation) from 2006 - 2010. In 2011, he was appointed a member of the ERC (European Research Council) Scientific Council.
Research at Academia can generate innovation, which can be exploited industrially. All major Universities have Technology Transfer Offices, which assist in patenting procedures, in the out-licensing of innovation and in the creation of spin-off companies.
Sometimes discoveries with an application potential arise from basic, curiosity driven research activities. Other times, scientists perform applied research with clear industrial goals in mind. These researchers may ask themselves whether their activities would best be performed in the Academic or in the Industrial Environment.
In my lecture, I will present:
Born in Rome (Italy) on 1 May 1963, Dario Neri studied
Chemistry at the Scuola Normale Superiore of Pisa, graduating with a thesis on
the synthesis and characterization of complex polyunsaturated secondary
metabolites, isolated from higher plants. He earned his doctorate in chemistry
under Professor Kurt Wüthrich in the Institute of Molecular Biology and
Biophysics at the ETH Hönggerberg in 1992. His dissertation was awarded the ETH
Zurich silver medal. With an EU Bridge Bursary, he spent four years at the
Cambridge Centre for Protein Engineering, Medical Research Council, where he
worked under the supervision of Sir Gregory Winter. He has now been a Professor
at the ETH Zurich since 1996.
The research of the group Neri focuses on the engineering of therapeutic
antibodies for the therapy of cancer and other angiogenesis-related disorders.
Other research activities include the chemical proteomic discovery of novel
vascular markers of pathology and the development of DNA-encoded chemical
libraries. Dario Neri is a co-founder of Philogen and Philochem. These companies have brought seven antibody-based products into
multicenter clinical trials in patients with cancer.
Dario Neri has published over 200 articles in peer-reviewed scientific
journals. He is the recipient of the ISOBM Abbott Prize 2000, of the
Amgen-Dompe' Biotec Award 2000, of the Mangia d'Oro 2001, of the Prous Award
2006 of the European Federation of Medicinal Chemistry, of the Robert-Wenner-Prize
2007 of the Swiss Cancer League, of the SWISS BRIDGE Award 2008 and of the Prix
Mentzer of the French Medicinal Chemistry Society.
«Will one corporate culture influence your potential for success?»
We will introduce Roche Diagnostics International (please note this is not Roche Pharma Basel) and provide personal accounts as Uni ZH Alumni on what we do, how we got there and what the biggest changes & challenges were for us to get where we are. We will also give some insider tips on how to apply, what you should pay particular attention to when finding a new position and what professional possibilities may await you in Rotkreuz. In the end, there will be a Q&A session starting with a discussion on academia vs industry, which may go wherever you take it- We look forward to seeing you there!
Erica Bogan is originally from Costa Rica, where she studied Biotechnological Engineering. In 2004, she obtained a Master's Degree in Molecular and Cellular Biology from the University of Heidelberg and then went on to do her PhD in the lab of Michael Hengartner at the University of Zürich, where she studied the function of a p53 binding protein in apoptosis and DNA damage in C. elegans. After her Phd, Erica switched gears and took on a role as scientific consultant at Kelly Scientific Resources and has now been working as a recruiting specialist at Roche Diagnostics International since October 2011.
Since 2011 Sebastian Kirbach works as Lifecycle Project Manager at Roche Professional Diagnostics. In this (matrix) function he supports the proceeding of the Lifecycle's R&D project portfolio by providing and challenging information regarding budget and timeline of individual projects. As certified Project Management Professional (PMP) he also assists in the development and implementation of project management process and best practices. Prior to this position he worked as consultant in a medium-sized consultancy and as an intern at the SWA Portfolio Management of Roche Professional Diagnostics. Sebastian obtained a PhD degree in Neuroscience (Brain-Research-Institute Zurich), an MBA with focus on International Business (Hult International Business School, Boston, USA), a Master in Advanced Studies of Applied Ethics (University of Zurich), and a diploma in Biochemistry (University of Leipzig, Germany).
Thomas Grau studied biochemistry at the University of Zurich. In 2010, he received his PhD in microbiology from the University of Zurich. During his PhD-thesis he mainly focused on the biosynthesis pathway of lipoproteins - which are virulence factors of Mycobacterium tuberculosis. As a postdoc at the Institute of Medical Microbiology in Zurich, he worked on antimicrobial resistance mechanisms in Mycobacterium tuberculosis and the evaluation of novel drug targets to combat Tuberculosis. Thomas joined Roche Diagnostics International in January 2012 as a department project leader and software test manager in the department of system integration.
Thanks to a broad recruitment experience and a large number of interview trainings with students and doctoral students, the members of ETH Career Center do know not only the typical questions asked in first job interviews but they also know about the uncertainties of candidates. ETH Career Center presents a self-produced video, which shows a job interview situation with typical first questions, good and critical answers but also frequently observed uncertainties. On the basis of the video and additional comments they show you what you can expect in a first job interview, what stands behind the questions and which is the best way to demonstrate your skills.
Evelyne Kappel has been working at ETH since 2008. Up to the end of 2009 she worked on the ACAP (Academic and Career Advisory Program) pilot project with responsibility for careers advice and employer relations. Since then Evelyne Kappel has advised and supported more than 200 ETH students and doctoral students on starting their careers, and has organised several careers events for students and companies. Before joining ETH, Evelyne Kappel spent more than three years with an executive search company specialising in finding and placing proven management talent. Evelyne Kappel has a wide knowledge of the Swiss jobs market and of the relevant requirements made of graduates. She is happy to share this knowledge, based on many years of counseling and recruitment experience, with students and doctoral students in order to advise them on starting their careers and to give them individual support.
Before joining ETH he worked in a variety of management positions in Human Resources. At Hewlett Packard Switzerland and AXA Winterthur he was HR Director and a member of the extended management board. Martin Ghisletti has a degree in business administration from the University of St. Gallen (HSG). Martin Ghisletti has an extensive knowledge of the jobs market, and is familiar with what companies think and do as part of their university recruitment and general careers management activities. His valuable skills and experience have been built up on the basis of many performance reviews and interviews, and he is happy to share them with students and doctoral students, both in personal counseling and at events, helping them to plan their careers.
Presentation about what to expect when faced with a Recruitment Process and Assessment Center in the job search.
Florian T. Wagner is currently a Senior HR Consultant for the consulting boutique Executive Consulting Group Ltd., where he passionately leads Executive Assessments, 360° Feedback Projects and Talent Management Projects, using his background in Psychology, his recently obtained MBA in the HULT intl. Business School and his international experience as his best assets. During his interesting professional career he has worked for several companies and institutions like the University of Zurich or the Police department of the City of Zurich, where he was project manager in the psychology department. Other than his professional achievement, Florian is Major of the Swiss army, have been amateur World Champion of Long Distance Duathlon and part of the Swiss National Team of Duathlon. Currently he is an avid mountaineer, marathon runner and cyclist.
Academic clinical trials are clinical trials not funded by pharmaceutical or biotechnology companies for commercial interests, but initiated and conducted by researchers of Universities or University Hospitals in order to promote and optimise medicinal therapies. The trials are a valuable component of the health care system. Typical areas of academic clinical trials are the translational studies in which knowledge from “the bench” is brought to “the bed” (the patients), the optimisation of already existing therapies, less frequent indications, outcome studies, diagnostic or interventional trials. Thus, academic clinical trials may for instance test how a combination of registered drugs may improve treatment outcomes. Such research questions are not the primary focus of for-profit companies. Due to the need of interdisciplinary knowledge for such studies, academic clinical research offers more and more job opportunities for PhDs. PD Dr Senti und Dr sc. nat. Jürg Lustenberger will present the Clinical Trials Center CTC at the Center for Clinical Research, University and University Hospital Zurich as a model for the increasing need of professional staff in academic research.
Since 2006 PD Dr. med. Gabriela Senti is heading the Clinical Trials Center (CTC) at the Center for Clinical Research of the University and University Hospital Zurich. She has led the CTC to the certification according to ISO 9001:2008 and to the accreditation by the Swiss Medical Association FMH as a category A academic further education center for Pharmaceutical Medicine.
Dr. Senti is a Swiss Medical Association (FMH) board certified Specialist in Dermatology and Venerolgoy (1998), Allergology and Clinical Immunology (2001). Her scientific activities relate to experimental immunotherapy with a focus on clinical studies in developing novel methods of desensitization against Type 1-allergies. She has more than 15 years’ experience in conducting clinical trials and was Principal Investigator for numerous national and international trials. Her main work was developing the intranodal and the epicutaneous route of Specific Immunotherapy. Since 2005 she is a University Professional in Advanced Pharmaceutical Medicine (ECPM-Postgraduate Course) and member of the Swiss Association of Pharmaceutical Medicine. In 2009 she achieved the Venia Legendi in Pharmaceutical Medicine in the field of Translational Research Developing New Methods for Allergen Specific Immunotherapy at the University of Zurich.
Jürg Lustenberger studied biology specializing in systematic and ecological biology and received his PhD at the ETH Zurich in 1992. 1996 he gained the Teacher's Diploma at the ETH Zurich and 2001 the Diploma in Pharmaceutical Medicine of the Swiss Association of Pharmaceutical Professionals (SwAPP). After leading several projects in reforestation and pedagogic areas he joined a Swiss Contract Research Organization in 1996. Starting as a Clinical Research Associate he was soon promoted to clinical project manager. As a member of the management team and leader of the Clinical Research Department of Switzerland he was responsible for the operational and strategic management, budgeting and financial control of all clinical projects. During this time he gathered extensive experience in leading and managing national and international clinical trials in various indications. Since 1997 he is organizing and presenting GCP trainings for industry and academia. 2003 he joined a consulting company as a senior clinical project manager, responsible for pharmaceutical development projects in Europe. In May 2004 he gained certification as GCP auditor and since then he performed numerous audits in Western and Eastern Europe, South America, South Africa and USA. In December 2005 he joined a Biotech company as Head of Clinical Quality Management, responsible for the company’s compliance with GCP requirements. In November 2006 he was promoted to Head of Corporate Quality Management, responsible for the company’s quality management system and compliance with GxP requirements. Since 2007 he was additionally assuming responsibilities as GMP auditor in Europe and Asia. 2009 he joined the Clinical Trials Center (CTC) at the University Hospital Zurich as Head Quality Management and Deputy Head CTC and also worked part time as GCP and GMP consultant and auditor for the Pharma and Biotech Industry. At the CTC he is responsible for the Quality Management System of the CTC (ISO 9001:2008), performs audits and is involved in the educational program of the institute. Since July 2012, after reducing his engagement at CTC, he is CEO, auditor and consultant at SwissPharmAudit, a small company providing quality management services.
Dr Kevin Lynch will discuss the remarkable and tragic history of thalidomide (also known under the brand name "Contergan" in Germany) and how a successful biopharmaceutical company has developed as a consequence of the better understanding of the biology of thalidomide and related drugs. In this respect, he will explore the enormously important role scientists have played in the evolution of a company and the resulting benefits delivered to patients with a number of life-threatening diseases.
Dr Nicolas Leupin will talk about his experiences as a Swiss-trained medical oncologist and how he has been able to capitalize on his scientific and medical training to have impact on a number of drug development programs. Both will refer to the range of career opportunities that are open to life-science graduates in this industry.
An Australian trained physician, Kevin Lynch joined the Pharmaceutical Industry in 1993, continuing studies in Pharmaceutical Medicine. He gained his Membership of the Faculty of Pharmaceutical Medicine in 1998 by thesis, and was awarded Faculty Fellowship in 2004.
During 19 years in Clinical Development and Medical Affairs, he has managed all aspects of drug development, including many Phase I through to Phase III and post-registration studies, as well as establishing departments responsible for Drug Safety, Medical Communications and Medical Affairs. He was Oncology Medical Director for Novartis Australia and New Zealand, with developmental responsibility for Glivec, Tasigna, Exjade, Zometa, Femara, and Sandostatin, taking those products from early development through to the market place. In 2008 he joined Celgene Pty Ltd as Medical Director for Australia and New Zealand, and then as Director, Clinical Development and Medical Affairs, Asia-Pacific. At the beginning of 2011 he moved to Switzerland as Vice President, Clinical Research and Development for Europe. Kevin is co-author on more than 100 publications and abstracts at international meetings.
Nicolas Leupin is a Doctor of Medicine, graduate of the Faculty of Medicine at the University of Bern. He is a specialist in oncology. He joined Celgene in 2008 and is currently Director for Clinical Research and Development EMEA based in Switzerland. Before joining Celgene he worked at the Lausanne Cancer Center, in the Department of Oncology in Bern and was member of the Swiss Group for Clinical Cancer Research. Since 2010 Dr Leupin has been an lecturer for the MD-PhD Graduate School at the University of Bern.
Teaching is much more than day-to-day routine. Dr. Samuel Ginsburg - teacher for biology and chemistry at the Kantonsschule Wettingen will present some of his achievements to better link business and school. He invested huge efforts to build up an international network for teacher working in Life Science offering advanced training and a regular knowledge exchange beyond borders.
Dr. Samuel Ginsburg joined the study program for a teaching diploma for secondary education (Höheres Lehramt Mittelschulen) in 1981 and finished his education with a doctoral degree at EHT & University of Zurich. In 1993, he started to teach Biology and Chemistry at the Kantonsschule Wettingen. Besides working as a teacher he constantly improved the link between business and schools. The Biovalley College Network as well as an exchange progam for teacher working in Life Science between US-CH-GER-F emphasize his invested efforts. In 2008, he became the CEO of «Young Enterprise Switzerland», an association that aims to support practically oriented business training programs for pupils & students.
During the last one or two decades, many companies have started to realize that the protection of intellectual property (IP), especially for high-tech industry sectors, is becoming ever more important in a globalized world. In fact, some argue that IP rights are the most valuable assets a business owns, following its human capital, i.e. its people. The increased importance of IP rights has also resulted in an accelerated demand for highly educated people to draft, examine and manage IP. In life science, this demand is mostly focused towards specialists in the patent field and driven by the biotech and pharmaceutical industries. Thus job opportunities cover such positions as patent attorneys, paralegals, patent officers or patent portfolio managers.
Educated at the ETH Zurich and having received his PhD in biochemistry, he worked for several years at different research institutions in San Diego and Chicago. He then returned to Switzerland to work as a principal investigator in cancer research at the University of Basel where he obtained the title of a professor at the medical faculty. Several years ago he joined the patent department of the Swiss Federal Institute of Intellectual Property while remaining a regular lecturer in biochemistry at the University of Basel. He also teaches intellectual property at different Swiss universities and writes articles for several publications and newspapers on this topic.
Her talk will cover different aspects of a career in financial services. You will gain insight into a highly competitive and challenging business. Comparing and following long term performances of specific companies as well as gathering information to prepare a financial statement are only some of the requirements you have to fulfill to become a successful financial analyst.
Dr. Silvia Schanz originally studied Biochemistry at the University of Freiburg (Germany) before she started her PhD in cancer research at ETH Zurich in 2005. After receiving her doctoral degree, Silvia decided to leave her bench and initiated her career as a Financial Analyst at “Bank Vontobel AG” evaluating biotechnology and pharmaceutical companies on the Swiss market. During her third year – out of science - she became a “Certified International Investment Analyst“. In 2011, Silvia moved on to her next position as Equity Analyst for Global Healthcare at UBS Wealth Management. Half a year ago, she decided to take over a more communicative role and is now responsible for investor relations at the specialized biotech asset manager BB Biotech AG.
Many career opportunities await you in the start-up sector. Learn more about GlycoVaxyn here.
Michael Kowarik has graduated from the Institute of Biochemistry, ETHZ, in 2003, and performed a three year postdoctoral study at the same university in the microbiology institute. He has been working at GlycoVaxyn since 2006 as head of research, and is responsible for all research programs at GlycoVaxyn. Michael is a co-inventor of the proprietary technology of GlycoVaxyn and author of several publications in international scientific journals, including Science and EMBO.
McKinsey & Company is the world’s leading strategic management firm. But you don’t need a business background to work for us! Our consultants have a wide range of academic backgrounds, personal stories, and passions. Indeed, a number of our people are physicians or PhDs who started their professional career in a medical clinic or research lab before joining us.
We can offer many fascinating opportunities for life-sciences graduates, such as working on R&D or marketing issues in the pharmaceuticals industry or, maybe, developing a healthcare strategy for an entire nation. Consulting with McKinsey is a real “hands on” learning environment to grow and expand your knowledge and experience. And, we’re a dynamic network of diverse and highly motivated colleagues with a shared set of values and high professional standards.
We warmly invite you to attend out presentation at the Zurich Life Science Day 2013!
Petra Jantzer is a Principal in the Zurich office. Since joining McKinsey & Company in 1999, she has spent the majority of her time on pharmaceuticals and medical products and participated in a range of strategy, organization and operations projects. She is a core member of the European Pharmaceuticals Practice with a strong focus on research and development. In addition, Petra leads the women’s recruiting efforts in the Swiss office. Petra holds a PhD in immunology and spent several years in basic research developing a novel therapeutic approach for the treatment of renal cancer. She graduated from the Ludwig-Maximilians-University, Munich with an M.Sc. in molecular biology.
Beat Glogger will present career opportunities for scientists interested in going in the direction of science communication. What can I do in the field of science communication? Am I right for it? What kind of efforts are necessary for me to succeed in science communication? These are some the questions Dr. Glogger will answer during his presentation, using his own experience as a starting point.
Dr. Beat Glogger is a Swiss science journalist, communication trainer, and author.
He studied biology and biochemistry in Zurich, and was trained as a journalist at the Swiss Journalism School. After spending 14 years as a journalist, moderator and editor in chief of MTW in 1999 he became independent and founded his own science communication company Scitec-media (www.scitec-media.ch). He then lived for some years in Central America, where he produced reports for different European television stations and newspapers.
Since November 2009 the agency produces the weekly published science pages in the newspaper «20 Minuten».
Beat Glogger today is also a teacher for science journalism at the Swiss Journalism School and trains scientists for their work with the media.
He has published several books in the field of popular science and two novels. «Xenesis» was awarded 2005 with the Media Prize of Swiss Academy of Sciences. In 2008 he was appointed to the advisory board of the same academy and elected as «Swiss Science Journalist of the Year». 2010 he received an honorary doctor from the University of Zurich for his great achievements in communicating science.
Weitere Informationen zum Gebäude
By public transport you can reach us via Tram lines 7 and 14 at station «Zürich, Milchbuck» or Tram lines 9 and 10 at station «Zürich, Universität Irchel». You can easily plan your trip at SBB.
By car you can reach us at Winterthurerstrasse 190 in Zurich. There is a parking garage on campus. You may plan your trip with Goggle Maps.
